Farnesyltransferase-inhibitors exert in vitro immunosuppressive capacity by inhibiting human B-cells

Farnesyltransferase-inhibitors exert in vitro immunosuppressive capacity by inhibiting human B-cells

ObjectivesFarnesyltransferase inhibitors (FTI), which inhibit the prenylation of Ras GTPases, were developed as anti-cancer drugs. As additional target proteins for prenylation were identified in the past, it is likely that FTI have potential value for therapeutic purposes beyond cancer. The effect...

Full description

Bibliographic Details
Main Authors: Shilei Xu, Sebastian Dolff, Nils Mülling, Hagen S. Bachmann, Yang Dai, Monika Lindemann, Ming Sun, Oliver Witzke, Andreas Kribben, Benjamin Wilde
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Transplantation
Subjects:
B-cells
plasma cells
farnesyltransferase inhibitors
renal transplantation
humoral rejection
Online Access:https://www.frontiersin.org/articles/10.3389/frtra.2023.1233322/full

Internet

https://www.frontiersin.org/articles/10.3389/frtra.2023.1233322/full

Similar Items